/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Valued at a market cap of $9.2 billion, Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. The Wilmington, Massachusetts-based company partners with pharmaceutical, biotechnology, government, and academic institutions to help accelerate research and drug development. It is expected to announce its fiscal Q3 earnings for 2025 before the market opens on Wednesday, Nov. 5.
Before this event, analysts expect this healthcare company to report a profit of $2.32 per share, down 10.4% from $2.59 per share in the year-ago quarter. The company has a promising trajectory of consistently beating Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $3.12 per share in the previous quarter topped the consensus estimates by a notable margin of 24.8%.